INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. L'invention concerne des composés de form...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LITTLE, ANDREW J VAN EPPS, STACY A SCHRIMPF, MICHAEL R CHIEN, ELLEN YULIN TSAI SCHIEDLER, DAVID A BREINLINGER, ERIC C WEBSTER, MATTHEW P VARGO, THOMAS R KATCHER, MATTHEW H FRIEDMAN, MICHAEL M FRANK, KRISTINE E DUNSTAN, THERESA A COWART, MARLON D QIU, WEI SCANIO, MARC J HARDEE, DAVID J HEROLD, J. MARTIN ARGIRIADI, MARIA A LIU, HUAQING |
| description | Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
L'invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5 et n sont tels que définis dans la description, des compositions pharmaceutiques les comprenant, et des procédés de préparation et d'utilisation. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3090842A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3090842A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3090842A13</originalsourceid><addsrcrecordid>eNrjZDDy9PPwdPIM8Q8KVvB3UwiJDPIP9vRzVfD29HMMdlUwUvB1dfF0DHF1UQj2dPdz9PH0c-dhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsYGlgYWJkaOhsZEKAEAH6EmJg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING</title><source>esp@cenet</source><creator>LITTLE, ANDREW J ; VAN EPPS, STACY A ; SCHRIMPF, MICHAEL R ; CHIEN, ELLEN YULIN TSAI ; SCHIEDLER, DAVID A ; BREINLINGER, ERIC C ; WEBSTER, MATTHEW P ; VARGO, THOMAS R ; KATCHER, MATTHEW H ; FRIEDMAN, MICHAEL M ; FRANK, KRISTINE E ; DUNSTAN, THERESA A ; COWART, MARLON D ; QIU, WEI ; SCANIO, MARC J ; HARDEE, DAVID J ; HEROLD, J. MARTIN ; ARGIRIADI, MARIA A ; LIU, HUAQING</creator><creatorcontrib>LITTLE, ANDREW J ; VAN EPPS, STACY A ; SCHRIMPF, MICHAEL R ; CHIEN, ELLEN YULIN TSAI ; SCHIEDLER, DAVID A ; BREINLINGER, ERIC C ; WEBSTER, MATTHEW P ; VARGO, THOMAS R ; KATCHER, MATTHEW H ; FRIEDMAN, MICHAEL M ; FRANK, KRISTINE E ; DUNSTAN, THERESA A ; COWART, MARLON D ; QIU, WEI ; SCANIO, MARC J ; HARDEE, DAVID J ; HEROLD, J. MARTIN ; ARGIRIADI, MARIA A ; LIU, HUAQING</creatorcontrib><description>Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
L'invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5 et n sont tels que définis dans la description, des compositions pharmaceutiques les comprenant, et des procédés de préparation et d'utilisation.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190919&DB=EPODOC&CC=CA&NR=3090842A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190919&DB=EPODOC&CC=CA&NR=3090842A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LITTLE, ANDREW J</creatorcontrib><creatorcontrib>VAN EPPS, STACY A</creatorcontrib><creatorcontrib>SCHRIMPF, MICHAEL R</creatorcontrib><creatorcontrib>CHIEN, ELLEN YULIN TSAI</creatorcontrib><creatorcontrib>SCHIEDLER, DAVID A</creatorcontrib><creatorcontrib>BREINLINGER, ERIC C</creatorcontrib><creatorcontrib>WEBSTER, MATTHEW P</creatorcontrib><creatorcontrib>VARGO, THOMAS R</creatorcontrib><creatorcontrib>KATCHER, MATTHEW H</creatorcontrib><creatorcontrib>FRIEDMAN, MICHAEL M</creatorcontrib><creatorcontrib>FRANK, KRISTINE E</creatorcontrib><creatorcontrib>DUNSTAN, THERESA A</creatorcontrib><creatorcontrib>COWART, MARLON D</creatorcontrib><creatorcontrib>QIU, WEI</creatorcontrib><creatorcontrib>SCANIO, MARC J</creatorcontrib><creatorcontrib>HARDEE, DAVID J</creatorcontrib><creatorcontrib>HEROLD, J. MARTIN</creatorcontrib><creatorcontrib>ARGIRIADI, MARIA A</creatorcontrib><creatorcontrib>LIU, HUAQING</creatorcontrib><title>INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING</title><description>Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
L'invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5 et n sont tels que définis dans la description, des compositions pharmaceutiques les comprenant, et des procédés de préparation et d'utilisation.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDy9PPwdPIM8Q8KVvB3UwiJDPIP9vRzVfD29HMMdlUwUvB1dfF0DHF1UQj2dPdz9PH0c-dhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsYGlgYWJkaOhsZEKAEAH6EmJg</recordid><startdate>20190919</startdate><enddate>20190919</enddate><creator>LITTLE, ANDREW J</creator><creator>VAN EPPS, STACY A</creator><creator>SCHRIMPF, MICHAEL R</creator><creator>CHIEN, ELLEN YULIN TSAI</creator><creator>SCHIEDLER, DAVID A</creator><creator>BREINLINGER, ERIC C</creator><creator>WEBSTER, MATTHEW P</creator><creator>VARGO, THOMAS R</creator><creator>KATCHER, MATTHEW H</creator><creator>FRIEDMAN, MICHAEL M</creator><creator>FRANK, KRISTINE E</creator><creator>DUNSTAN, THERESA A</creator><creator>COWART, MARLON D</creator><creator>QIU, WEI</creator><creator>SCANIO, MARC J</creator><creator>HARDEE, DAVID J</creator><creator>HEROLD, J. MARTIN</creator><creator>ARGIRIADI, MARIA A</creator><creator>LIU, HUAQING</creator><scope>EVB</scope></search><sort><creationdate>20190919</creationdate><title>INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING</title><author>LITTLE, ANDREW J ; VAN EPPS, STACY A ; SCHRIMPF, MICHAEL R ; CHIEN, ELLEN YULIN TSAI ; SCHIEDLER, DAVID A ; BREINLINGER, ERIC C ; WEBSTER, MATTHEW P ; VARGO, THOMAS R ; KATCHER, MATTHEW H ; FRIEDMAN, MICHAEL M ; FRANK, KRISTINE E ; DUNSTAN, THERESA A ; COWART, MARLON D ; QIU, WEI ; SCANIO, MARC J ; HARDEE, DAVID J ; HEROLD, J. MARTIN ; ARGIRIADI, MARIA A ; LIU, HUAQING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3090842A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>LITTLE, ANDREW J</creatorcontrib><creatorcontrib>VAN EPPS, STACY A</creatorcontrib><creatorcontrib>SCHRIMPF, MICHAEL R</creatorcontrib><creatorcontrib>CHIEN, ELLEN YULIN TSAI</creatorcontrib><creatorcontrib>SCHIEDLER, DAVID A</creatorcontrib><creatorcontrib>BREINLINGER, ERIC C</creatorcontrib><creatorcontrib>WEBSTER, MATTHEW P</creatorcontrib><creatorcontrib>VARGO, THOMAS R</creatorcontrib><creatorcontrib>KATCHER, MATTHEW H</creatorcontrib><creatorcontrib>FRIEDMAN, MICHAEL M</creatorcontrib><creatorcontrib>FRANK, KRISTINE E</creatorcontrib><creatorcontrib>DUNSTAN, THERESA A</creatorcontrib><creatorcontrib>COWART, MARLON D</creatorcontrib><creatorcontrib>QIU, WEI</creatorcontrib><creatorcontrib>SCANIO, MARC J</creatorcontrib><creatorcontrib>HARDEE, DAVID J</creatorcontrib><creatorcontrib>HEROLD, J. MARTIN</creatorcontrib><creatorcontrib>ARGIRIADI, MARIA A</creatorcontrib><creatorcontrib>LIU, HUAQING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LITTLE, ANDREW J</au><au>VAN EPPS, STACY A</au><au>SCHRIMPF, MICHAEL R</au><au>CHIEN, ELLEN YULIN TSAI</au><au>SCHIEDLER, DAVID A</au><au>BREINLINGER, ERIC C</au><au>WEBSTER, MATTHEW P</au><au>VARGO, THOMAS R</au><au>KATCHER, MATTHEW H</au><au>FRIEDMAN, MICHAEL M</au><au>FRANK, KRISTINE E</au><au>DUNSTAN, THERESA A</au><au>COWART, MARLON D</au><au>QIU, WEI</au><au>SCANIO, MARC J</au><au>HARDEE, DAVID J</au><au>HEROLD, J. MARTIN</au><au>ARGIRIADI, MARIA A</au><au>LIU, HUAQING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING</title><date>2019-09-19</date><risdate>2019</risdate><abstract>Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
L'invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5 et n sont tels que définis dans la description, des compositions pharmaceutiques les comprenant, et des procédés de préparation et d'utilisation.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3090842A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| title | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LITTLE,%20ANDREW%20J&rft.date=2019-09-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3090842A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |